MY151025A - Buprenorphine derivatives and uses thereof - Google Patents

Buprenorphine derivatives and uses thereof

Info

Publication number
MY151025A
MY151025A MYPI20083500A MY151025A MY 151025 A MY151025 A MY 151025A MY PI20083500 A MYPI20083500 A MY PI20083500A MY 151025 A MY151025 A MY 151025A
Authority
MY
Malaysia
Prior art keywords
buprenorphine
buprenorphine derivatives
enhanced
derivatives
moderate
Prior art date
Application number
Other languages
English (en)
Inventor
Chapleo Christopher Bourne
Lewis John William
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of MY151025A publication Critical patent/MY151025A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20083500 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof MY151025A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
MY151025A true MY151025A (en) 2014-03-31

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20083500 MY151025A (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Country Status (21)

Country Link
US (1) US7964610B2 (enExample)
EP (1) EP2001891B1 (enExample)
JP (1) JP5167446B2 (enExample)
KR (1) KR101430626B1 (enExample)
CN (2) CN104151320A (enExample)
AU (1) AU2007231133B2 (enExample)
BR (1) BRPI0709157A8 (enExample)
CA (1) CA2647417C (enExample)
DK (1) DK2001891T3 (enExample)
ES (1) ES2432169T3 (enExample)
GB (1) GB0606124D0 (enExample)
IL (1) IL193917A (enExample)
MX (1) MX2008011984A (enExample)
MY (1) MY151025A (enExample)
NZ (1) NZ570997A (enExample)
PL (1) PL2001891T3 (enExample)
PT (1) PT2001891E (enExample)
RU (1) RU2435773C2 (enExample)
TW (1) TWI501969B (enExample)
WO (1) WO2007110636A1 (enExample)
ZA (1) ZA200807614B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511054B2 (en) 2006-09-22 2009-03-31 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
PT2307420E (pt) * 2008-04-24 2012-02-14 Janssen Pharmaceutica Nv Pró-fármacos de di-éster de nalmefeno
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
MX2018004835A (es) * 2015-10-26 2018-08-01 Orphomed Inc Etilenglicol eter de buprenorfina.
CA3016510A1 (en) 2016-03-09 2017-09-14 Indivior Uk Limited Abuse-resistant pharmaceutical formulations
CN109789137B (zh) 2016-09-13 2023-01-13 昱展新药生技股份有限公司 丁丙诺啡缓释制剂
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
KR102839314B1 (ko) * 2018-05-11 2025-07-29 에일러 파마슈티컬스 아이엔씨. 오래 지속되는 주사용 제제와 부프레노핀 유도체
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
ES2298323T3 (es) 1998-11-13 2008-05-16 Jagotec Ag Inhalador de polvo seco multidosis con reserva de polvo.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
JP2005523876A (ja) 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
JP5167446B2 (ja) 2013-03-21
RU2435773C2 (ru) 2011-12-10
CA2647417C (en) 2014-09-23
RU2008142527A (ru) 2010-05-10
MX2008011984A (es) 2008-10-03
EP2001891A1 (en) 2008-12-17
NZ570997A (en) 2011-08-26
TWI501969B (zh) 2015-10-01
CA2647417A1 (en) 2007-10-04
US20100234412A1 (en) 2010-09-16
PT2001891E (pt) 2013-10-30
WO2007110636A1 (en) 2007-10-04
BRPI0709157A2 (pt) 2011-06-28
EP2001891B1 (en) 2013-07-24
AU2007231133A8 (en) 2011-08-25
AU2007231133A1 (en) 2007-10-04
CN104151320A (zh) 2014-11-19
AU2007231133B2 (en) 2011-09-01
JP2009531406A (ja) 2009-09-03
AU2007231133A2 (en) 2008-10-16
PL2001891T3 (pl) 2014-03-31
GB0606124D0 (en) 2006-05-03
KR101430626B1 (ko) 2014-08-18
IL193917A (en) 2014-12-31
BRPI0709157A8 (pt) 2018-04-24
DK2001891T3 (da) 2013-11-04
CN101410402A (zh) 2009-04-15
ES2432169T3 (es) 2013-12-02
TW200806672A (en) 2008-02-01
KR20080105124A (ko) 2008-12-03
US7964610B2 (en) 2011-06-21
ZA200807614B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
MY151025A (en) Buprenorphine derivatives and uses thereof
WO2009089494A3 (en) Pharmaceutical compositions
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2010132882A8 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2009079451A3 (en) Compositions and methods of promoting wound healing
WO2009106831A3 (en) Pharmaceutical composition comprising naltrexone
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
WO2012073047A3 (en) Compositions and methods
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP1729761A4 (en) TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
PL1998730T3 (pl) Nowy system uciskowy do leczenia i zapobiegania patologiom pochodzenia żylnego
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
WO2007121279A3 (en) Cancer treatment method
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies
GB0607306D0 (en) Debounce circuit and method
WO2012054093A3 (en) Acyl piperidine inhibitors of soluble epoxide hydrolase
AU2007225022A8 (en) Non-codeine opioid analgesic process and formulations
MX2009004142A (es) Metodo para prevenir o tratar sindrome metabolico.
AU2010298020A8 (en) Combination
WO2008063853A3 (en) Cancer treatment method
ZA200904455B (en) Methods for the treatment of alcohol abuse, addiction and dependency
WO2007123847A3 (en) Treatment of melanoma